This trial showed significantly improved survival in the quizartinib arm and led to the approval of this drug by US FDA for newly diagnosed FLT3 ITD-positive AML, increasing the treatment options for this group of patients [19]. The gene discussed is FLT3; the disease is acute myeloid leukemia.